People: Galapagos NV (GLPYY.PK)

GLPYY.PK on OTC Markets Group

22.72USD
20 May 2013
Price Change (% chg)

$0.32 (+1.41%)
Prev Close
$22.40
Open
$22.70
Day's High
$22.82
Day's Low
$22.70
Volume
1,040
Avg. Vol
2,401
52-wk High
$27.00
52-wk Low
$13.86

Search Stocks

Summary

Name Age Since Current Position

Raj Parekh

 53 2004 Non-Executive Chairman of the Board

Onno van de Stolpe

 54 1999 Chief Executive Officer, Executive Director

Guillaume Jetten

 2009 Chief Financial Officer

Andre Hoekema

 2005 Senior Vice President - Corporate Development

Christopher Newton

 2010 Senior Vice President Galapagos Services

Piet Wigerinck

 2012 Chief Scientific Officer

Harrold van Barlingen

 48 2005 Non-Executive Director

Katrine Bosley

 2013 Independent Non-Executive Director

Werner Cautreels

 61 2009 Non-Executive Independent Director

Howard Rowe

 2010 Non-Executive Independent Director

Vicki Sato

 2011 Non-Executive Independent Director
» Insider Trading

Biographies

Name Description

Raj Parekh

 Dr. Raj Parekh has been Non-Executive Chairman of the Board of Galapagos NV since July 2004. He is Chairman of the Nomination and Remuneration Committee and Member of the Audit Committee. He is a General Partner at Advent Venture Partners. He co-founded Oxford GlycoSciences (OGS) where he served as Chief Scientific Officer from 1988. He has founded or served on the Board of several Life Sciences Companies in the United States and Europe including Celldex Therapeutics, EUSA Pharma, Cellnovo, Thiakis and AMT. He is currently Member of the Supervisory Board of the Novartis Venture Fund. He received his Bachelor of Arts in Biochemistry and Doctorate in Philosophy in Molecular Medicine from the University of Oxford, where he has also been a Visiting Professor.

Onno van de Stolpe

 Mr. Onno van de Stolpe has served as Chief Executive Officer and Executive Director of Galapagos NV since June 1999. He founded Galapagos in 1999 while he was Managing Director Genomics at Introgene (now Crucell). Prior to joining Introgene in 1998, he was Managing Director of Molecular Probes Europe. He established this European headquarters after joining Molecular Probes in the United States. Previously, he worked for the Netherlands Foreign Investment Agency in California, where he was responsible for recruiting biotech and medical device companies to locate in the Netherlands. Mr. van de Stolpe started his career as Manager Business Development at MOGEN in Leiden. He received a Master of Science degree from the Agricultural University in Wageningen.

Guillaume Jetten

 Mr. Guillaume Jetten has been Chief Financial Officer of Galapagos NV since July 1, 2009. Before joining the Company, he was Executive Board Member and Chief Financial Officer (CFO) of SDU Holding BV, a privately owned company specialized in publishing and identification documents. Previously, he was CFO of Wolters Kluwer Health in Chicago, where he drove initiatives to improve global financial and operating processes and create synergies of scale. He also served as Vice President Group Accounting at Wolters Kluwer NV and held various positions at Merck, Sharpe & Dohme BV. Mr. Jetten holds a Masters degree in Economics from the University of Maastricht and is a Certified Registered Accountant.

Andre Hoekema

 Dr. Andre Hoekema, Ph.D, has served as Senior Vice President of Corporate Development at Galapagos NV. He joined Galapagos in March 2005 from Invitrogen Corporation, where he was Managing Director of Corporate Development Europe. He has 20 years of biotech experience from positions at Molecular Probes Europe (Managing Director), Crucell (Director of Business Development), DSM Life Sciences and MOGEN (Research and Project Management) and Genentech, Inc. Dr. Hoekema has a Doctorate in Philosophy degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the United States.

Christopher Newton

 Dr. Christopher (Chris) Newton, Ph.D. has been Senior Vice President Galapagos Services at Galapagos NV. He previously served as the Company's Senior Vice President Biofocus. Dr. Newton joined the Company in 2005. Between 2000 and 2005, he was a founding scientist and CSO and Board Director at Argenta Discovery Ltd. From 1979 to 2000, he held a variety of senior management positions in both research and development in the Rhone-Poulenc group of companies, working on a variety of projects, some of which reached clinical trials. Dr. Newton holds a degree in Natural Sciences from the University of Cambridge and is Emeleus chemistry prize holder of that university. He earned his Doctorate in Philosophy at the University of Sheffield in 1979, for which he was awarded the Turner Prize. Dr. Newton has been appointed to visiting academic fellowships and professorships associated with the University of Warwick (1994-1998) and the University of Essex (1995-1999) during his industrial career.

Piet Wigerinck

 Dr. Piet Wigerinck, Ph.D., has served as Chief Scientific Officer of Galapagos NV since April 18, 2012. He was Senior Vice President - Development from April 1, 2008. Dr. Wigerinck joined the Company in April 2008 from Tibotec (a subsidiary of Johnson & Johnson) where he was Vice President of Drug Discovery, Early Development and CM&C, and Member of the Management Board. He started his professional career as medicinal chemist at Janssen Research Foundation in 1992. He then joined Tibotec in 1998, where, under his leadership, TMC114 (PrezistaTM) was selected and moved forward into clinical trials. He brings over 15 years of research and development experience from both big pharma and biotech to Galapagos. Mr. Wigerinck holds a Doctorate in Philosophy from the Catholic University of Louvain and is inventor on more than 25 patent applications.

Harrold van Barlingen

 Dr. Harrold van Barlingen, Ph.D., has been Non-Executive Director of Galapagos NV since 2005. He is Managing Director and Founder of Thuja Capital. Prior to founding Thuja Capital, he headed the life science effort of AlpInvest Partners. Previously, he was at the Boston Consulting Group, where he worked as a Consultant in management and strategy. Prior to BCG, Mr. van Barlingen headed the Benelux office of the Lewin Group (a Quintiles subsidiary); an international firm specialized in the field of health economy. He holds a MSc in Medical Biology and a Doctorate in Philosophy in the area of cardiovascular diseases, both from the University of Utrecht.

Katrine Bosley

 Ms. Katrine Bosley has been Independent Non-Executive Director of Galapagos NV since February 27, 2013. Ms. Bosley was until recently Chief Executive Officer of Avila Therapeutics, a covalent drug company. Prior to Avila, she was Vice President Business Development at Adnexus Therapeutics, a company developing a new class of protein therapeutics. She joined Adnexus from Biogen Idec where she had roles in business development, commercial operations, and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners. She graduated from Cornell University with a Bachelor of Arts in biology and completed the Program for Management Development at Harvard Business School.

Werner Cautreels

 Dr. Werner Cautreels, Ph.D., has been Non-Executive Independent Director of Galapagos NV since June 2, 2009. He is President and Chief Executive Officer (CEO) of Selecta Biosciences. Previously, Dr. Cautreels was Global CEO of Solvay Pharmaceuticals until it was acquired by Abbott Laboratories in February 2010. Prior to joining Solvay he was employed by Sanofi, Sterling Winthrop and Nycomed Amersham in a variety of R&D management positions in Europe and in the United States. Dr. Cautreels was a director of Innogenetics NV (Gent, Belgium) and of Arqule Inc. (Woburn, United States) from 1999 to 2006. He was President of the Belgian-Luxemburg Chamber of Commerce for Russia and Belarus until June 2010. He graduated from the University of Antwerp, gaining a Doctorate in Chemistry, specializing in Mass Spectrometry. He also holds a Bachelors degree and Master of Science in Chemistry from the University of Antwerp. He received his management and financial education from the Harvard Business School. He is Member of the Company's Nomination and Remuneration Committee and Audit Committee.

Howard Rowe

 Dr. Howard Rowe, J.D., has been Non-Executive Independent Director of Galapagos NV since August 5, 2010. He was previously Managing Director with Goldman Sachs where he had multiple Healthcare responsibilities over his 12 years at the firm. His most recent roles at Goldman Sachs were as part of the European Special Situations and Principal Strategies teams where he established and led the private healthcare investing effort. During that time he served on the boards of EUSA Pharma, Healthcare Brands International, MedAvante, SmallBone Innovations and Ikonisys. Prior to his investing activities, Dr. Rowe was Senior Member of the European Healthcare Investment Banking team, where he advised numerous corporate clients on Mergers & Acquisitions and corporate finance activities. Before joining Goldman Sachs, he was Corporate Lawyer with the law firm Sullivan & Cromwell. Dr. Rowe received his Bachelor of Science in Psychobiology from the University of Southern California, and his Juris Doctor from Harvard Law School. He is also Member of the Nomination and Remuneration Committee.

Vicki Sato

 Dr. Vicki Sato, Ph.D., has been Non-Executive Independent Director of Galapagos NV since April 26, 2011. Dr. Sato was President of Vertex Pharmaceuticals from 2000 to 2005. Prior to her role as President, she held various positions at Vertex including Chief Scientific Officer, Senior Vice President of R&D, and Chair of the Scientific Advisory Board. Before joining Vertex, Dr. Sato was Vice President of Research at Biogen, Inc, where she also participated in the Executive Management of the company and served as Member of the Scientific Board. Dr. Sato is Professor of Management Practice at Harvard Business School and Professor of the Practice in the Department of Molecular and Cell Biology, Harvard University. She also serves as a business advisor to Atlas Venture and other enterprises in the biotechnology and pharmaceutical industries. Dr. Sato holds a Bachelor of Arts (Geology) from Radcliffe College and Master of Arts and Doctorate in Philosophy degrees (both in Biology) from Harvard University and completed postdoctoral work at the University of California Berkeley and Stanford Medical Center.

Basic Compensation

Name Fiscal Year Total

Raj Parekh

 --

Onno van de Stolpe

 480,784

Guillaume Jetten

 --

Andre Hoekema

 --

Christopher Newton

 --

Piet Wigerinck

 --

Harrold van Barlingen

 20,000

Katrine Bosley

 --

Werner Cautreels

 20,000

Howard Rowe

 20,000

Vicki Sato

 20,000
As Of 30 Dec 2011

Insider Trading

» Full list on Insider Trading
Search Stocks